Relmada Therapeutics, Inc. is a public, clinical-stage specialty pharmaceutical company founded with the mission to develop innovative treatments for pain management. The company focuses on repurposing established drug products and researching new chemical entities to address chronic pain conditions. Their primary product pipeline includes REL-1017, a novel NMDA receptor antagonist aimed at treating major depressive disorder and neuropathic pain. Relmada's market focus is on providing effective, non-opioid alternatives for pain relief, addressing a significant unmet need in the healthcare sector.
Notable figures affiliated with Relmada Therapeutics include key researchers and executives who have contributed to the company's advancements in pain treatment. The company has garnered attention from prominent investors and has participated in high-profile conferences such as the Goldman Sachs Annual Global Healthcare Conference and the Jefferies Global Healthcare Conference. Among its key achievements, Relmada has published promising results from its Phase 3 Reliance I study of REL-1017 in The Journal of Clinical Psychiatry, underscoring its potential impact on pain management and mental health treatment.
Quick Facts
When was Relmada Therapeutics' last funding round?
Relmada Therapeutics' most recent funding round was for $150M (USD) in December 2021.
How much disclosed funding has Relmada Therapeutics raised?
As of Dec 8, 2021, Relmada Therapeutics has disclosed funding of $191.1M (USD).
